International Journal of Radiation Oncology, Biology, Physics 1992: Vol 22 Index

9 Pages·1992·1.7 MB·English

AUTHOR INDEX
Volume 22, 1992
Aass, N., 1057 Brock, W. A., 241 Darling, J. L., 103 Fine, S., 853
Abe, M., 597, 601, 973, 1009 Brown, J. M., 79, 553, 681, 701, 759 Davis, L. W., 569 Fischer, J. J., 87
Abitbol, A. A., 175 Brucher, J.-M., 275 Davis, M. A., 499 Fitzpatrick, P. J., 859
Ablin, A. R., 13 Brunel, P., 1071, 1099 Davis, R. K., 181 Fornander, T., 887
Abrams, M. J., 607 Bruton, C., 23 Day Ill, R. S., 765 Fortan, L., 224
Adams, G. E., 467, 473, 545, 707, 717 Bujnoski, J. L., 175 Dea, D., 1093 Fossa, S. D., 1057
Ahmad, K., 1065 Bump, E. A., 731 Degraff, W. G., 593 Fowler, J. F., 219, 1163
Ahn, D., 295 Bush, R. S., 847, 853, 859 Delanian, S., 1071, 1099 Frankel, J., 139
Akazawa, C. N., 1093 Bush, S., 935 DeLaPaz, R. L., 47 Frankel, K. A., 47
Akuta, K., 1009 Busutti, L., 585 Delclos, L., 941 Frhling J., 979
Albright, N. W., 1093 Buswell, L., 565, 573, 577 Delgado, G., 1105 Fyles, A. W., 833, 847, 867
Alexander III, E., 573, 577 DeLuca, A. M., 65
Algazy, K., 791 Camel, H. M., 905 Dembo, A. J., 835, 847, 853, 859, 867 Gademann, G., 375
Allalunis-Turner, M. J., 765 Carlsson, J., 259 Denekamp, J., 437 Galakatos, A. E., 905
Anderson, R. F., 537, 553 Caruso, F. S., 607 De Neve, W., 224 Galvin, J. M., 1083
Archambeau, J. O., 287, 311, 383 Castro, R., 295 Dennis, I., 721 Garcia, D. M., 905
Ardalan, B., 511 Cattanach, B. M., 473 Dennis, M. F., 485, 751 Garcia-Angulo, A. H., 589
Armour, E., 109 Cerce, B. A., 731 Denny, W. A., 537, 553, 693 Garg, P. K., 593
Ayyagari, S., 1043 Chang, F., 191 DeVol, E., 1065 Garg, S., 593
Chang, P., 191 Dewhirst, M., 989 Gasperin Jr., P., 979
Bacher, J. D., 65 Chaplin, D. J., 451, 459, 463, 685, 737 Dobler, K., 765 Gauger, G., 295
Bagshaw, M. A., 999 Charreau, I., 581 Dobrowsky, E., 875 Geard, C. R., 495, 613
Bailey, S. M., 649 Chassagne, D., 581 Dobrowsky, W., 875 George, S. L., 989
Baillet, F., 1071, 1099 Chatham, J. C., 95 Dobson, H., 1065 Giaccia, A. J., 681, 759
Bando, M., 561 Chen, G., 1075, 1164 Dodge, R. K.. 989 Giandomenico, C. M., 607
Banerjee, S. S., 929 Chen, M.-S., 913 Douple, E. B., 607 Ginsberg, M. S., 175
Barnes, W., 1105 Cheng, E., 1083 Dowsett, R. J., 1083 Glass, J., 803
Barrett, J. M., 1071 Choi, N. C., 1162 Dritschilo, A., 1105 Glatstein, E., 195
Barron, G. M., 765 Cholon, A., 759 Dubray, B. M., 241 Gleave, E. N., 925
Barton, J., 925 Chow, C. H., 167 Duran, G. E., 821 Glickson, J. D., 95
Battista, J., 159 Christensen, K. L., 451, 455 Durand, R. E., 689 Goffman, T. E., 195, 803
Baumann, M., 1163 Christianson, T. J. H., 519 Duthie, M. B., 929 Golden, R. N., 7.
Beck-Bornholdt, H.-P., 1163 Chu, G. L., 1093 Goliaei, B., 1029
Bedford, P., 721 Chua, T., 859 Edwards, D. I., 661, 677 Gospodarowicz, M. K., 833, 859, 1161
Bedwinek, J., 23 Clark, R. M., 859 Edwards, H. S., 717 Gottleb, C., 505
Belfi, C. A., 477 Clegg, S., 989 Einhorn, L. H., 17 Gozy, M., 979
Bender, H., 225 Cline, J. M., 403 Ekwelundu, E., 167 Graham, M. M., 199
Benedetto, P., 511 Clubb, B., 1065 El-Akkad, S., 1065 Grant, W., 989
Beningo, K. A., 549 Cobb, L. M., 655 Ellerbroek, N., 1164 Grau, C., 115, 407, 415, 421
Benoliel, J., 897 Cohen, A. M., 139 Elliott, W., 545, 549 Grdina, D. J., 813
Bensadoun, R.-J., 897 Coia, L., 791 Emami, B., 1163 Greer, S., 505
Benson, K., 191 Cole, S., 545, 707, 717 Emrich, J., 225 Gregroire, V., 275
Bergsagel, D. E., 859 Coleman, C. N., 483, 565, 569, 573, Eng, T. Y., 1093 Greiner, R. H., 333
Bertoni, F., 585 577, 731 Enker, W. E., 139 Grierson, J. R., 199
Brub, L. R., 817 Collier, J. M., 295 Ensminger, W. D., 499 Griffin, T. W., 199
Bhatia, S. P. S., 1043 Comis, R., 791 Epperson, R., 1083 Grigsby, P., 577, 905, 1117
Bhujwalla, Z. M., 95 Connor, A. M., 807 Eschwege, F., 581 Grisell, D. L., 65
Biaglow, J. E., 665, 671 Constantinidis, I., 95 Eshleman, J., 225 Grunbaum, Z., 755
Biedermann, K. A., 681 Coray, A., 333 Evans, M. L., 199 Guichard, M., 949
Binger, M., 713 Corry, P., 109 Ezz, A., 159 Gupta, B. D., 1043
Black, P., 225 Cosmatos, D., 569 Gutin, P., 295
Blattmann, H., 333 Counsell, C. J. R., 467 Fabrikant, J. I., 47 Guttenberger, R., 795
Bleehen, N. M., 443, 721, 953 Cowan, D. S. M., 541 Falcone, F., 585 Gyergyay, F., 785
Blomquist, E., 259 Cox, R. S., 999 Falk, S. J., 721
Bodell, W. J., 489 Crowell, C., 305 Farah, S., 817 Hacker, T., 655
Bonner, J. A., 519 Cummings, B. J., 833 Fenster, A., 159 Hahn, S., 803
Bradley, F. C., 607 Cuscela, D., 803 Fenton, B. M., 447 Halberg, F. E., 13
Brady, L. W., 225 Ferri, E., 585 Hale, R. J., 929
Breccia, A., 585 Dadparvar, S., 225 Fessenden, P., 999 Hall, E. J., 221, 613, 743, 747
Bremner, J. C. M., 467, 717 Daftari, I., 295 Feun, L., 511 Hamada, K.., 31
Brenner, D. J., 221 Dale, P., 813 Fielden, E. M., 545, 707 Hamamoto, K., 31
Britten, R. A., 769 Darcourt, J., 897 Fieldler, J. A., 175 Hanks, G., 791
Al5
Harmer, C., 919 Kitagawa, T., 321 Low, N., 1075 Munro, P., 159
Harnsberger, H. R., 181 Klein, J. L., 37 Loyd, M. D., 167 Murayama, C., 557
Harrelson, J., 989 Kligerman, M. M., 799 Lupton, G., 803 Murray, J. C., 431
Harrington, F. S., 195 Kochhar, R., 1043 Lyman, J. T., 247 Myrianthopoulos, L., 1075, 1164
Harris, J. R., 577 Koh, W.-J., 199
Harris, R., 1083 Kolozsvary, A., 515 MacPhail, H. S., 533 Nagasawa, H., 561
Hassenbusch, S. J., 477 Komaki, R., 1164 MacVittie, T. J., 773 Nagata, Y., 1009
Hayes, J. K., 181 Kooistra, K. L., 713 Majima, H., 1019 Nair, S., 225
He, S., 799 Koprowski, H., 225 Malaise, E. P., 581 Nath, R., 1125, 1131
He, Z. Y., 747 Kovacs, M. S., 681 Manchul, L. A., 847, 867 Naylor, M. A., 707
Heffner, T. G., 549 Kramer, J. H., 13 Mao, H.-S., 115 Neben, T. Y., 573, 577
Hei, T. K., 743, 747 Kramer, R. A., 573, 577 Marcial, V. A., 569 Needham, M., 1083
Held, K., 665 Krigel, R., 791 Marienberg, E. S., 175 Negi, P. S., 1043
Hendry, J. H., 241 Krishna, C. M., 803 Marijnissen, J. P. A., 963 Nethersell, A. B. W., 721
Henkelman, R. M., 251 Krishnasamy, S., 1075 Marion, H. S., 505 Ngo, F. Q. H., 477
Henze, G., 1083 Kristjansen, P. E. G., 451 Iviarkoe, A. M., 175 Nielsen, J. E., 407
Hickson, I., 759 Kristl, J., 737 Martinez, A. P., 701 Nieves, J., 225
Hill, S. A., 437 Krohn, K. A., 199, 755 Martinez, A., 109 Nishimoto, S.-I., 597, 601
Hinz, J. M., 623 Kuten, A., 905 Masunaga, S.-I., 973, 1009 Nishimura, Y., 1009
Hiraoka, M., 1009 Kuwahara, G., 1093 Masuoka, M., 597 Nishiyama, Y., 31
Holloway, R., 1105 Kwok, T. T., 411, 525 Matsu-Ura, S., 31 Nolan, J., 655
Holman, M., 1089 Matthay, K. K., 13 Noll, L., 565, 577
Honess, D. J., 443, 953 LaDine, J. K., 403 Mauch, P., 1159 Notarus, M. I., 383
Hong, J.-H., 913 Lagrange, J.-L., 897 Maulard, C., 1071, 1099 Nowakowski, V. A., 295
Hori, H., 561 Landy, H. J., 175 Maybaum, J., 499
Horsman, M. R., 415, 421, 451, 455, Lane, R. G., 167 McArthur, P., 1065 O'Brien, P. J., 639
459 Langer, M., 325 McBride, W. H., 57 O'Hara, J. A., 607
Host, H., 1057 Larson, D. A., 1093 McClelland, R. A., 541, 817 Ohishi, H., 1109
Houdek, P. V., 175 Lartigau, E., 949 McCormack, T., 225 Oleson, J. R., 989
Housset, M., 1071, 1099 Lau, D. H-M, 821 McCulloch, W., 791 Olive, P. L., 397, 689
Howes, A. E., 577 Lavey, R. S., 3 McDonald, S., 147 O'Neill, P., 707
Hoyt, W. F., 1093 Lawrence, T. S., 499, 519 McElligott, M. A., 607 Ono, K., 973
Huart, J., 1071, 1099 Lax, I., 887 McGinnis, D. J., 731 Onoyama, Y., 561
Hughes, C. S., 87 Lazzaro, B., 225 McMillan, T. J., 103 Onyekwere, O. C., 37
Hunter, N. R., 795 Leavitt, D. D., 181 McShan, D. L., 361 Orr, K., 195
Hurwitz, S. J., 573, 577 Lee, D.-J., 569 Mechling, J. A., 131 Orton, C. G., 222
Lee, E. R., 999 Meek, A. G., 1139 Osborne, S., 159
Iketani, H., 31 Lee, I., 425 Meigooni, A. S., 1125, 1131 Otsuka, M., 71
Inayama, S., 561 Lee, £23 Meistrich, M. L., 71 Overgaard, J., 115, 407, 415, 421, 451,
Irvin, C. G., 87 Leichner, P. K., 37 Melillo, A., 1131 455
Ishikawa, T., 321 Lemmon, M., 79, 701 Mendenhall, W. M., 3
Ito, T., 601 Leopold, K. A., 989 Menke, D., 79 Pai, S., 1139
Iwata, K., 1109 Leopold, W., 545, 549 Meredith, R. F., 1051 Pass, H. I., 65
Lespinasse, F., 949 Meyer, J. L., 999 Pasteels, J.-L., 979
Jaffray, D. A., 159 Lester, S. G., 17 Migneco, O., 897 Patchen, M. L., 773
Jo, S., 1009 Levin, C. V., 355 Milas, L., 795 Patel, F., 1043
Johansson, H., 887 Levin, W., 847, 867 Miller, A., 147 Patterson, B. J., 859
Levitt, S. H., 123, 425, 1157 Miller, D. W., 383 Pauwels, O., 979
Kagiya, V. T., 589, 597, 601 Lewellen, T. K., 199 Miller, R. W., 195 Payne, D., 223
Kahn, J., 1019 Lewin, A. A., 175 Minchinton, A. I., 79, 681, 701 Payne, R., 1083
Kanagasabapathy, V. M., 541 Lewis, A. D., 759, 821 Minsky, B. D., 139 Peacock, J. H., 103, 769
Kann, R., 333 Li, Y. P., 1009 Miralbell, R., 305 Pedroni, E., 333
Kao, M.-S., 905 Li, Z., 1089 Mitchell, J. B., 483, 593, 665, 671, 803 Perez, C. A., 905, 1117
Kapp, D. S., 999 Lichter, A. S., 361, 1147 Miyamoto, C., 225 Peters, C. E., 463
Kataoka, M., 31 Lin, F.-J., 913 Miyata, Y., 557 Peters, G. E., 1051
Kawamura, M., 31 Lin, J.-C., 123 Mizuno, M., 451 Peters, G. J., 785
Kelley, M., 87 Lindstrom, M. J., 1163 Moeller, J. H., 181 Peters, L. J., 941
Kelsen, D. P., 139 Linggood, R., 265 Molteni, A., 623 Peters, N., 919
Kemeny, N., 139 Linstadt, D. E., 295 Moore, I. M., 13 Peters, R., 791
Khan, K., 935 Liu, F.-F., 223 Moore, S. K., 727 Peterson, M. A., 1083
Khil, M. S., 515 Liu, T., 799 Morabito, M., 225 Petti, P. L., 295
Kijewski, P., 325 Liu, Y., 799 Mori, T., 557 Petty, A., 23
Kim, J. H., 425, 515 Livesey, J. C., 755 Morita, S., 321, 1047 Phillips, T. L., 295, 489, 569
Kim, R. Y., 105i Livingstone, A., 511 Morphis Il, J. G., 17 Piao, C. Q., 747
Kim, S. H., 515 Lo, E. H., 47 Morrell, L., 511 Pinedo, H. M., 785
Kim, Y. T., 623 Lo; Y.C.,57 Mukai, M., 1047 Pirkowski, M., 1105
Kinsella, T. J., 65 Loeffler, J. S., 573, 577 Munkel, G., 333 Pisciotta, V., 175
Kiss, R., 979 Logue, J. P., 929 Munro, A. J., 859 Pollart, D. J., 701
Al6
Popescu, G., 1105 Schwade, J. G., 175, 505 Sur, R. K., 1043 Vincent, P. W., 549
Porter, A. T., 159 Sebolt-Leopold, J., 545, 549, 619 Sutcliffe, S. B., 859, 1161 Vinczan, A., 737
Porter, E., 87 Serago, C. F., 175 Sutherland, R. M., 411, 447, 525 Virk, N. S., 677
Powell, S., 919 Sethi, T., 1043 Suto, M., 545, 549 Vitu, L., 949
Preston, W., 383 Shankland, E. G., 755 Sutton, H., 1075 Vriesendorp, H. M., 37
Pringle, J. F., 847, 853, 867 Shao, Y., 37 Suzuki, A., 557
Prionas, S. D., 999 Share, F., 191 Su—zuTki , T., 557 Wada, T., 1109
Prosnitz, L. R., 989 Shargel, L., 573
Pryzant, R. M., 941 Sharma, S. C., 1043 Wahlen, S., 343
Tada, T., 561 Waldman, S., 511
Purdy, J. A., 147 Shaw, E. G., 1161
Takahashi, M., 1009 Wallen, C. A., 727
Shibamoto, Y., 597
Tamada, T., 1109 Walton, M. I., 643, 649
Quadri, S$. M., 37 Shirai, A., 1109
Tanabe, Y., 557 Wambersie, A., 275
Quinney, R. M., 473 Shoji, T., 557
Tang, S. G., 913 Wang, C. C., 1155
Quistorff, B., 451 Siemann, D., 391, 393, 629, 697, 781
Tangeman, R., 287 Wang, J., 601
Sigdestad, C. P., 807
Tannock, I. F., 881 Wang, Z., 109
Raaphorst, G. P., 1035 Sigurdson, E. R., 139 Tatsuzaki, H., 265, 369 Wannenniacher, M., 375
Rabbani, A., 1029 Sikic, B. I., 821
Rackover, M., 225 Silva, J. M., 639 TTeafyflto,r ,M .J,. 4M7.7 G., 3 WWaarrad,, WR.., M7.2,1 13, 1093
Rajabi, H., 1029 Simm, J., 847, 853, 867
Raleigh, J. A., 403 Simpson, J. R., 905 Thames, H. D., 241 Ward, W. F., 623
Ramsay, J. R. S., 721 Sims, C. S., 807 Thomas, C., 467 Wardman, P., 537, 751
Thomas, D., 1105 Warenius, H. M., 769
RRaassemyu,s sJe.n S,. , J1.,9 94 89 SSiinndgehl,a r,D . WP.. , F1.,0 4635 TThhoommapss,o n,G. WM..,, 983457 , 853, 867 WWaatstsse,r mMa.n ,E .,T .4 3H1. , 391, 569, 629
Rathman, M., 403 Singh, M. T., 1043
Rauth, A. M., 541, 817, 875 Thrall, D. E., 403 Wetete, J.P... 95
Skarsgard, L. D., 737 Thum, P., 333 Weichselbaum, R., 813, 1164
Rawlings, G. A., 847, 853, 867 Skinner, A. L., 1083 Ting, L.-L., 477 Weinhous, M. S., 1089
Reddy, R., 511 Skov, K. A., 533 Tishler, R. B., 495, 613 Wen, P., 577
Reinstein, L. E., 1139 Skwarchuk, M. W., 737
Tocher, J. H., 661 Wendt, C. D., 941
Reynolds, A., 1083 Slater, J. D., 287, 311, 343, 383
Tochner, Z. A., 65 Weppelmann, B., 1051
Richardson, M. E., 781 Slater, J. M., 287, 311, 343, 383
Tomiyama, T., 1109 Wheeler, K. T., 727
Richman, S., 511 Slessinger, E. D., 1117
Torrisi, J., 1105 Wheeler, R. H., 1051
Riechman, B., 139 Slevin, N. J., 925
Tosto, L. M., 681, 701 Whelan, T. J., 853
Riese, N., 565, 573, 577 Smee, R., 223
Tracy, M., 701 White, J., 537, 751
Roberts, P. B., 537, 553 Smit, B., 343
Treskes, M., 785 White, R., 769
Rockwell, S., 87 Smith, K. A., 431
Trotter, M. J., 397 Wiley, J. N., 549
Rodgers, J., 1105 Smith, R., 1083
Ts’ao, C.-H., 623 Willett, C. G., 369
Rose, M.-A., 565 Sofield, J., 23
Tsang, R., 859 Williams, J. R., 37
Rosen, I. I., 167 Song, C. W., 123, 425
Tsuji, Y., 1109 Williams, K. B., 437
Ross, G. Y., 489 Sougawa, M., 1019
Roth, B. J., 213 Souza, L. M., 773 Tsujii, H., 321 Williams, S. D., 17, 213
Tsunemoto, H., 321, 1047 Williamson, J. F., 1117
Rozec, C., 1071, 1099 Spears, W. T., 17
Tucker, J. A., 989 Wilson, D. J., 737
Rubin, P., 1, 147, 569, 831 Spencer, S. A., 1051
Tucker, S. L., 241 Wilson, W. R., 537, 553, 693
Rutqvist, L. E., 887 Star, W. M., 963
Tuttle, S. W., 671 Withers, H. R., 57
Ryan, T. P., 131 Steel, G. G., 103
Steinberg, G. K., 47 Woo, D. V., 225
Stephens, M. A., 707 Uchida, H., 1109 Wood, P. J., 467, 473
Sakaguchi, M., 557
Salter, M. M., 1051 Steplewski, Z., 225 Uhl, V., 489 Woodcock, M., 431
Urano, M., 1015, 1019 Wootton, R., 721
Saltz, L., 139 Stetson, P. L., 499
Samulski, T., 989 Stine Ac 1: 908 Urie, M. M., 265, 369 Workman, P., 391, 629, 631, 643, 649,
Stidley, C., 935 Urtasun, R. C., 235, 765 713, 721
Sancho-Garnier, H., 581
Stier, M. A., 549 Uto, F., 1109 belo
Sandler, H. M., 361
f i Wyman, M., 755
Sansom, J. M., 473 Stinson, R. L., 37
Santos, O., 505 Stone, H. B., 79 van de Geijn, J., 195
Sasai, K., 597, 601 Storme, G., 224 van der Vijgh, W. J. F., 785 Yabuki, H., 87
Sato, C., 557 Stratford, I. J., 467, 473, 529, 545, 707, van der Wilt, C. L., 785 Yamamoto, I., 1109
Satoh, T., 561 717 Van Houtte, P., 979 Yang, X., 103
Savaraj, N., 511 Stratford, M. R. L., 485, 751 van Laar, J. A. M., 785 Yoshimura, H., 1109
Scavone, S. V., 619 Stridhar, K., 511 van Putten, W. L. J., 963
Scheffler, B., 799 Strohbehn, J. W., 131 van Zijl, P., 693 Zalutsky, M. R., 593
Schien, P., 791 Sturgeon, J. F. G., 847, 853, 867 Varnes, M. E., 671 Zeman, E. M., 403
Schiff, P. B., 613 Sugget, N., 643, 649 Versteeg, J. A. C., 963 Zhang, Z., 799
Schultheiss, T. E., 241 Sugita, T., 597 Vijayakumar, S., 1075, 1164 Zhou, L., 597
Schultz, H. P., 1065 Suit, H. D., 233, 305 Vikse, C., 397 Zusag, T. W., 147

SUBJECT INDEX
Volume 22, 1992
BNCT, 259 CDFI1 mice, 451, 455
Bolus material, 191 Cell(s)
Bone marrow transplatation (BMT), 37 A549, 489
Accelerators, 383 Borderline epithelial ovarian neoplasms, 867 Cervical carcinoma, 495
ACE inhibitors, 623 Boron neutron capture therapy, 259 Cycle, 525, 613
Acid Brachytherapy, 181, 573, 577, 905, 1071, HeLa, 515
Ethacrynic, 821 1117, 1125, 1131 Hypoxic, 557, 607
Flavone acetic, 79, 431, 437 Endobronchial, 23 LS178Y, 639
Hydroxamic, 561 Brain, 47 Mammalian, 533
N-(phosphonacetyl)-L-aspartic, 505 Metastasis, 17 Quiescent, 973
Abnormal large nuclei, 71 Neoplasm, 225 SCC VII-To, 875
Acridine, 553 Tumors, 573 U87 mg, 489
Orange, 537, 751 Brain/plasma partition coefficient, 601 U1, 489
Adjuvant therapy, 139 Breast cancer, 887, 1099 Cell, hypoxic, 557, 607
Adriamycin, 459 Bromodeoxyuridine, 485 Sensitizer, 569, 573, 577, 581, 593
Adverse effects, 949 Sensitization, 495 Toxicity, 817
A549 BSO, 533, 593, 681 Cellular
Cells, 489 BUdR, 485 Radiosensitivity, 769
Human carcinoma, 665 BUN, 71 Recovery, 103
Afterloading, 1105 Buthionine sulfoximine, 519, 765, 781 Central nervous system, 287
High dose rate, 23 BW12C, 721 Cervical
Ir-192, 1071 Cancer, 919
Age, 919 Cc Carcinoma cells, 495
Agent(s) Lymphadenopathy, 1071
Antiemetic, 549 Cervix, 343, 355
Bis-bioreductive, 693 Calcium channel blockers, 443 Carcinoma, 349
Radiation-protective, 807 Cancer(s) Charged particle(s), 311, 383
AK-2123, 589 Breast, 887, 1099 Radiotherapy, 295, 375
Alkylating agent, 619 Cervical, 919 Chemical
Alopecia, 803 Esophageal, 1043, 1047 Modifiers, 573, 577
Alpha-beta ratio, 3 Gastrointestinal, 721 Response modifiers, 585
Amino acid analogue, 593 Head and neck, 3, 181, 1065 Chemodectoma, 919
Am-241, 1125 Lung, 1009 Chemopotentiation, 619
Analogues, 701 Ovarian, 835, 847, 853 Chemosensitization, 727
Analysis * Prostate, 935 Chemosensitizer, 765
Digital cell image, 979 Rectal, 139, 1109 Childhood, 287
Sensitivity, 325 Recurrent head and neck, 1051 Chlorambucil cytotoxicity, 737
Animal tumors, 607 Testicular, 1057 Cinnarizine, 443
Antiemetic agents, 549 Uterine cervix, 589 Cisplatinum, 459, 785
Antimutagen, 813 Canine tumors, 403 Clinical correlation, 235
Assay Kaptopril, 623 Coagulation, 431
Endogenous-spleen-colony, 807 Carbogen, 415 Cognitive function, 13
Micronucleus, 973 Carbon monoxide, 421 Collateral resistance, 769
Astrocytoma, 287 Carboxyhemoglobin, 407, 421 Combination therapy, 1047
High grade, 225 Carcinogenesis, 795 Combined
AZT, 813 Carcinoma(s) Modality therapy, 835, 853
A549 human, 665 Treatment, 999
Cervix, 349 Comparative treatment planning, 265, 305,
C3H mammary, 115 369
C3H mouse mammary, 451, 455
Complication(s), 311, 343, 847, 853, 999,
Beagle dog, 37 Endometrial, 905
1043
Beam’s eye section, 1089 Esophageal, 321
Late, 3
BES, 1089 Head and neck, 581
Computed
Bioreduction, 545, 677 Human squumous cell, 525
Tomography (CT), 181
Bioreductive In vivo C3H mammary, 415, 421
Tomography-emission, 195
Alkylation, 639 Lewis lung, 505
Tomography-x-ray, 195
Compounds, 697 Lung, 65, 585
Cyiotoxin, 701 Nasopharyngeal, 941 Computer-assisted, 195
Drugs, 631, 689, 707, 717, 747 Ovarian, 1105 Computer-controlled
Bis-bioreductive agent, 693 Rectal, 369 Radiation therapy, 167
Blood-brain barrier, 47 Squamous cell, 407 Stereotaxic guide, 175
Blood flow, 415, 421, 447 Uterine cervix, 31 Computer
Regional cerebral, 47 Cardiac function, 897 Graphics, 147
Tumor, 459, 463, 467 Cardiovascular disease, 887 Workstation, 147
Biood perfusion, 451 Carotid Conformal therapy, 325
Tumor, 477 Body, 919 Continuous infusion, 573, 577
Blood pressure, 451, 455 Cannulation, 455 Contrast media, 477
Mean arterial, 79 CB 1954, 643 Copper complexes, 607
BL-10, 681 CCI-103F, 403 Cs-137, 1125
C3H mammary carcinoma, 115 Radiation, 807 Radial dose, 1125
In vivo, 415, 421 Tumor bed, 963 Renal, 443
C3H mouse mammary carcinoma, 451, 455 Volume, 57
CT simulator, 175 EGF, 259
Cumulative minutes, 989 86-RbCl, 421 G
Cyanomorpholino doxorubicin, 821 Extraction technique, 415
Cyclophosphamide, 727 Elasto-gel, 191
Cystafos, 807 Electron Gadopentetate dimeglumine, 477
Cysteine, 751 Capture, 537 Gastrointestinal cancer, 721
Cytotoxicity Energy, 191 Glioblastoma multiforme, 265
Chlorambucil, 737 Spin resonance, 803 Glioma(s), 103, 259, 287
Hypoxic cell, 697 ELISA, 403 Malignant, 259, 765
Emesis, 549 Glomus jugulare, 919
D EMT6, 553 Glucose, 95
Tumor, 505, 557 Glucose-6-phosphate dehydrogenase, 671
Endobronchial brachytherapy, 23 Glutathione, 665
Damage Endogenous-spleen-colony assay, 807 Depletion, 533
DNA, 677 Endometrial carcinoma, 905 Hydroperoxides, 671
Inhibition of repair of sublethal radiation, Endothelial, 431 Peroxidase, 665, 751, 781i, 817
1035 Endothelium, 623 Glutathione-S-transferase, 665, 759, 821
Oxidative, 677 Energy Granulocyte colony-stimulating factor, 773
DelaRyeepda ir of potentially lethal, 973 EPlheocttorno,n , 19119 1 GGRS6H3,1 7688,1 437
Fluorescence, 537 Enzymes, 631 Depletion, 821
Radiation injury, 47 Enzymology, 643 Gynecological malignancies, 1117
Depth dose, 235 EOS, 643, 713
Design and development, 383 EPID, 1139 H
Diamide, 671 Epidermal growth factor, 225, 259, 525
Diaphragmatic metastases, 1105 Esophageal
DDiiaczuimrairdoinly,l 6b5e5n zoquinones, 649 EtanCCiaadnracczeoirln,eo ,m a1,0545 37,,3 2151 6054,7 569, 573, 577, 585, HeadC aracnidn onmeac,k, 548017
DDiigsietaasle cell image analysis, 979 731, 743 Recurrent cancer, 1051
Cardiovascular, 887 Ethacrynic acid, 821 Head and neck cancer(s), 3, 181, 1065
DNAHB,ao sdeg4sk8,5i ,n6 ’6s51,3 7,3 77, 518 59 EEEtxvhtoiekorefnodas l, pob8te0ea7nmt i alisr,r ad4i7a tion, 1043 HHHeeeaaLtvaR,ye c c1uei1rlo5lrns es,n, t5,31 251 1 051
Binding, 693 Hematoporphyrin derivative, 963
Damage, 677 F Hemoglobin, 407
Intercalation, 553 Level, 919
Nucleosides, 661 Hemopoiesis, 773
Strand breaks, 677 Factor(s) Heterogeneity, 103
Targeting, 541 Epidermal growth, 525 HGPRT, 813
Dose-volume histogram, 1093 Granulocyte colony-stimulating, 773 High dose rate
Dose(s) Predictive, 999 Afterloading, 23
Calculations, 1131 Prognostic, 859 Irradiation, 31
Depth, 235 Failure pattern, 859 High grade astrocytoma, 225
Low, 533 Field study, 375 High LET, 295
Dose effect, 1043 Finite elements, 131 Hodgkin’s disease, 37, 859
Relationship, 963 Fission spectrum, 807 HPLC, 485, 553
Dosimetry, 147, 191, 1117, 1131 5-chloro-2'-deoxycytidine, 505 Human, 225
In vivo, 1109 5-fluoro-2'-deoxyuridine, 499 Cell lines, 769
Thermal, 989 5-fluorodeoxycytidine, 505 Glial tumors, 613
Doxorubicin, 519 5-fluorouracil, 499, 785, 875, 1051 Squamous cell carcinoma, 525
Drug(s) 5-hydroxytryptamine, 463 Hydralazine, 79, 455, 463, 467, 473, 477, 953
Bioreductive, 631, 689, 707, 717, 747 5-iodo-2'-deoxyuridine, 499 Hydroperoxides, 665
Radiation, 875 Flavone acetic acid, 79, 431, 437 Glutathione, 671
Resistance, 639 Flunarizine, 443, 473 Hydroxamic acid, 561
DT-diaphorase, 639, 643, 649 Fluorescent Hydroxyurea, 1051
Dynamic, 333 Derivative, 485 Hypercard, 147
Probes, 751 Hyperthermia, 109, 115, 123, 131, 989, 999,
E Fluorinated 2-nitroimidazole, 593 1009, 1035
Fluorine-modified nitroazole, 601 Hyperthermia and radiation, 1015
fluoromisonidazole, 199 Hypoxia, 115, 411, 545, 589, 689, 717, 721,
Early effects, 897 Foot reaction, 1015 731, 747
Education, 147 4-bromomethyl-7-methoxycoumarin, 485 Markers, 403
Effect(s) 14-C-deoxyglucose autoradiography, 95 Tumor, 199, 397
Adverse, 949 Fractionated radiotherapy, 259 Hypoxic, 701
Chlorambucil and hydralazine on mouse Fractionation, 3, 109, 415 Fraction, 415, 421
tumors (SCCVII), 737 Free radicals, 677 Hypoxic cell(s),557, 607
Dose, 1043 FSa-II tumor, 1019 Cytotoxicity, 697
Early, 897 FU/LV/PALA, 511 In solid tumors, 87
Late 65 Function Radiosensitizer, 561, 597
Long-term, 887 Cardiac, 897 Sensitizer(s), 569, 573, 577, 581, 593
Low pH, 737 Cognitive, 13 Toxicity, 817
Mouse, 71 Morphonuclear modifications, 979
Weight, 71 Mortality, 887
KIH-802, 561 Mouse, 57
Ifosfamide, 727 KITH-802, 561 Kidney, 71
Image correlation, 195 KIN-804, 561 Mammary tumor, MXT, 979
Imaging, 1139 KIN-831, 561 MTT, 655
Magnetic resonance, 477 MXT mouse mammary tumor, 979
Oncological, 251 L
On-line, 1139 N
Portal, 159
Therapy, 159 Labeling index, 71
Video-based portal, 159 Lactate, 95 Nasopharyngeal carcinoma, 941
Immunofluorescence staining, 973 Laser Doppler, 455, 459, 463 Neoplasm(s)
Immunotherapy, 225 Late Borderline epithelial ovarian, 867
Implants Complications, 3 Brain, 225
Interstitial, 1131 Effects, 65 Testicular, 17
Permanent, 1131 Radiation damage, 71 Nephrectomy, 71
Incorporation, 485, 489 Late-responding tissue, 1015 Neuropsychological, 13
Index Leukemia, 13 Neurotoxicity, 565
Labeling, 71
Lewis lung carcinoma, 505 Neutron(s), 807
Therapeutic risk, 601 LS178Y cells, 639 Therapy, 321, 1065
Indolequinone(s), 649, 713 Liver, 953 Nicotinamide, 79, 425, 451
Indwelling intra-uterine tube, 349 Local Nifedipine, 443
Infra-diaphragmatic radiotherapy, 1057 Control, 311, 343 19-F magnetic resonance spectroscopy
Inhibition of repair of sublethal radiation Recurrence, 1099 (MRS), 467
damage, 1035 Long-term effects, 887 Nitracrine, 693
Insertion depth, 131 Low dose(s), 533 Nitracrine-N-oxide, 693
Integration of diagnostic and therapeutic Rate irradiation, 109, 495 Nitroacridines, 537
procedures, 175 Low pH effect, 737 Nitroimidazole, 561
Interactions, 875 On chlorambucil uptake, 737 Nitro radical anion, 661
Interferon, 765 Lung Nitroxide, 803
Internship and residency, 1147 Cancer, 1009 NLA-1, 553
Interstitial Carcinoma, 65, 585 Normal tissue(s), 655
Implants, 1131 Injury, 623 Tolerance, 65
Light delivery, 963 Lymphoma, 791, 929 N-oxide metabolism, 693
Intracavitary N-(phosphonacetyl)-L-aspartic acid (PALA),
Irradiation, 31, 1043, 1117 M 505
Radiation therapy, 1109 Nuclear magnetic resonance spectroscopy,
Therapy, 349 755
IntrCacoenlcleunltarr ations, 751 Magnetic resonance, 251 Nude mouse, 37
Drug concentration, 541 Imaging, 477
Intraoperative, 1105 Magnetic resonance spectroscopy (MRS) O
Irradiation, 65 19-F, 467
Intratumor pH, 123 Nuclear, 755
In vitro, 875 31-P, 467, 473 OER, 533
In vivo, 115 Malignant glioma(s), 259, 765 OK-432, 1047
C3H mammary carcinoma, 415, 421 Mammalian cells, 533 Oncogenic
Dosimetry, 1109 Maxillary sinus, 305 Potential, 747
Light dosimetry, 963 Mean arterial blood pressure, 79 Transformation, 743
lodine-125, 225, 1125, 1131 Mechanisms, 631 Oncological imaging, 251
Iododeoxyuridine, 489 Medical eduction, 1147 On-line imaging, 1139
Ionizing radiation, 671, 759 Melphalan, 731, 769 Optic nerve, 1093
Iridium-192, 181, 935, 1099, 1125 Meningioma, 1093 Sheath, 1093
Afterloading, 1071 Metabolic rate, 597 Ovarian
Irradiation Metabolism, 631 Cancer, 835, 847, 853
External beam, 1043 N-oxide, 693 Carcinoma, 1105
High dose rate, 31 Tumor, 451, 467 Tumors of low malignant potential, 867
Intracavitary, 31, 1043, 1117 Metal, 607 Oxidative
Intraoperative, 65 Metastasis(es) Damage, 677
Low dose rate, 109, 495 Brain, 17 Stress, 803
Pion, 333 Diaphragmatic, 1105 Oxygen, 415, 447
Preoperative, 905 Meth-A tumor, 515 Consumption tumor, 397
Prophylactic cranial, 13 Metronidazole, 661 Tension, 949
Proton, 259 Mice, 807, 949 Utilization, 407
Total body, 791 CDF1, 451, 455 Oxygenation, 451
Micronucleus assay, 973 Tumor, 425
Microwave antennas, 131
Miralva, 1117
Misonidazole, 115, 553, 795
Mitomycin C, 643, 721, 875
KHT, 781 Modulation, 759 Palladium-103, 1131
Sarcoma, 477 Resistance, 821 Para-aortic lymph nodes, 355
Tumor, 953 Monoclonal antibody, 225 Paralysis, 57
Kidney, 953 Morbidity, 925 Paraspinal tumors, 295
Function, 953 Interstitial implants of prostate, 935 Parotid pleomorphic adenoma, 925
A21
Particle therapy, 349 Radiation and hyperthermia, 1015 Sarcoma(s), 989
Partition coefficient Radiation-protective agents, 807 KHT, 477
Brain/plasma, 601 Radiation therapy, 31, 139, 847, 887, 897, Unresectable soft tissue, 333
Tumor/plasma, 601 989, 1009, 1093, 1105 SCC VII, 553
Pd-123, 1125 Computer-controlled, 167 Tumor, 557
Pediatric, 287 Intracavitary, 1109 SCC VII-To cells, 875
Solid tumors, 375 Proton, 369 sc 9L tumor, 727
Penetrating ability, 1125 Radiofrequency, 1009 Sensitivity
Pentose cycle, 671 Radioimmunoglobulin therapy (RIT), 37 Analysis, 325
Pentoxifylline, 425 Radioprotection, 773, 803 Thermal, 1019
Perfluorochemical emulsions, 87 Radioresponse, 425 Sensitizer(s), 731
Perfluorooctylbromide, 87 Radiosensitivity, 103, 1019 Hypoxic cell, 569, 573, 577, 581, 593
Permanent implants, 1131 Cellular, 769 Radiation, 565
Permeability, 431 Radiosensitization, 489, 515, 533, 537, 545, Side effects, 1057
Peroxide, 665 561, 589, 717, 1035 Simulator, CT, 175
Electrode, 665 Radiosensitizer(s), 557, 573, 577, 585, 607, Skin, 115
p50, 407 613, 707, 765 Smoking, 407, 421
PFOB, 467 Hypoxic cell, 561, 597 Sm-145, 1125
pH, 95 Radiosurgery, 47 Spheroids, 689, 693
Intratumor, 123 Radiotherapy, 13, 115, 195, 287, 311, 343, Spinal cord injury, 57
Pharmacokinetics, 56!, 565, 701, 713 361, 383, 585, 835, 919, 925, 929, 979 Spontaneous tumors, 473
Phase I, 511 Charged particle, 295, 375 Squamous cell carcinoma, 407
Phosphate metabolites, 95 Fractionated, 259 SR 4233, 643, 677, 681, 701
Phosphorothioates, 807 Infra-diaphragmatic, 1057 SR 2508, 565, 569, 573, 577, 593, 731
Photodynamic therapy, 963 Localization, 159 Stage, 919
Photofrin II, 963 Precision, 251 Stereotaxic
Photon(s), 769 Stereotaxic, 175 Computer-controlled guide, 175
Energy, 191 3D coniormal, 235, 333 Radiotherapy, 175
Pimonidazole, 553 Randomized trial, 581 Strand breaks, DNA, 677
Pion irradiation, 333 Rectal cancer, 799 Structure-activity relationships, 649
Polarographic method, 949 Rat, 37 Sulfur-substituted 3-nitrotriazoles, 597
Poly(ADP-ribose) synthetase, 619 Rectal cancer, 139, 1109 Surgery, 919, 925
Portal, 1139 Randomized trial, 799 Survival, 311, 431
Aperture, 1089 Rectal carcinoma, 369
Portal imaging, 159 Recurrence, 925, 941
T
Vidoe-based, 159 Local, 1099
Positron emission transaxial tomography, 199 Recurrent
Potentially lethal damage repair, 973 Head and neck cancer, 1051
Precision radiotherapy, 251 Tumors, 1019 Taxol, 613
Predictive factors, 999 Redox cycling, 639 Technique, 1093, 86-RbCI extraction, 415
Predictor of response, 199 Reductases, 655 Temperature distributions, 131
Preoperative irradiation, 905 Reduction-oxidation state, 755 Temporary interstitial implantation, 935
Prognostic factors, 859 Regional cerebral blood flow, 47 Testicular
Prophylactic cranial irradiation, 13 Reirradiation, 1051 Cancer, 1057
Propranolol, 463 Renal function, 443 Neoplasms, 17
Prostate, 361 Reoxygenation, 411 Tetrahydrouridine, 505
Cancer, 935 Repair, 1015 T-50, 989
Proton(s), 287, 355, 343, 383 Residency training in radiation oncology, Therapeutic
Beam therapy, 265, 305 1147 Management, 867
Irradiation, 259 Resident training, 147 Risk index, 601
Radiation therapy, 369 Resistance Therapy
Therapy, 321, 349 Collateral, 769 Adjuvant, 139
Drug, 639 Boron neutron capture, 259
Q Modulation, 821 Combination, 1047
Resonance Combined modality, 835, 853
Electron spin, 803 Conformal, 325
Quality assurance, 159, 1139 Magnetic, 251 Imaging, 159
Quiescent cells, 973 Response Intracavitary, 349
Predictor, 199 Neutron, 321, 1065
Radiation, 411, 525 Particle, 349
R Re-treatment, 941 Photodynamic, 963
Retroperitoneal tumors, 375 Proton, 321, 349
Rhabdomyosarcoma R-1, 963 Proton beam, 265, 305
Radial dose function, 1125 RIF-1 tumors, 95 Radiation, 31, 139, 847, 887, 897, 989,
Radiation, 415, 421, 795, 859, 875, 1047 Risk estimates, 743 1009, 1093, 1105
Delayed injury, 47 Ro-03-8799, 459 Radioimmunoglobulin, 37
Drug, 875 RP-170, 557 Salvage, 1071
Effects, 807 RSU 1069, 459, 549 Thermal
Hepatitis, 37 Dosimetry, 989
Induced, 623 Parameters, 999
lonizing, 671, 759 Sensitivity, 1019
Late damage, 71 Thermoluminescent sheet, 1109
Lethality, 665 Thiols, 751, 755
Protector, 799 Salvage 13-C and 31-P NMR in vivo, 95
Response, 411, 525 Curietherapy, 1099
Sensitizer(s), 499, 565 Therapy, 1071
A22
31-P magnetic resonance spectroscopy Canine, 403 U
(MRS), 467, 473 Control, 421, 963
Three-dimensional (3D) EMT-6, 505, 557
Conformal radiotherapy, 235, 333 FSa-ll, 1019 U87 mg cells, 489
Treatment planning, 361 Heterogeneity, 765 Unresectable soft tissue sarcoma, 333
-misonidazole, 655 Human glial, 613 U1 cells, 489
Thyroid, 929 Hypoxia, 199, 397, 403 Uterine cervix
Tissue(s) KHT, 953 Cancer, 589
Late-responding, 1015 Metabolism, 451, 467 Carcinoma, 31
Normal, 655 Meth-A, 515
Normal tolerance, 65 MXT mouse mammary, 979
T-90, 989 Necrosis, 437
Tolerance, 325 Oxygenation, 87, 425
Tomography-emission computed, 195 Oxygen consumption, 397
Tomography-x-ray computed, 195 Oxygen unloading capacity, 407 Vaginal applicator, 1117
Tonsil, 311 Paraspinal, 295 Vascular
Topoisomerase, 519 Pediatric solid, 375 Thermotolerance, 123
Topotecan, 515 Perfusion, 79 Tumor, 397
Total body irradiation, 791 Recurrent, 1019 Verapamil, 443
Transplantable tumors, 473 Regression, 919 Video-based portal imaging, 159
Treatment planning, 167, 181, 195, 325, Retroperitoneal, 375 Volume effect, 57
1131 RIF-1, 95
Comparative, 265, 305, 369 SCC VII, 557 Ww
Three-dimensional, 361 se 9L, 727
Trenimon, 639 Spontaneous, 473
Trial, Randomized, 581 Transplantable, 473 WR-1065, 751
T-10, 989 Vasculature, 397 WR-151326, 813
Tumor(s), 79, 701 Tumor/plasma partition coefficient, 601 WR-2721, 773, 785, 791, 795, 799
Animal, 607 T.V. cameras, 159
Bed effect, 963 2-nitroimidazole(s), 403, 553, 565, 573, 577,
Blood flow, 459, 463, 467 593, 727, 817 Y
Blood perfusion, 477 Fluorinated, 593
Blood volume, 467 Linked phenanthridine, 541
Brain, 573 Nucleoside analog, 557 Yb-169, 1125